Home Operations Utilizing Stimulation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Eric Porges, PhD
- Phone Number: 352-294-5838
- Email: eporges@ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32643
- University of Florida McKnight Brain Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants for one cohort will be adults between the ages of 18-55, consistent with the typical college population
- Participants for the other cohort will be adults between the ages of 56 - 85. Participants must read and write English.
Exclusion Criteria:
- Major medical illnesses including diagnosed severe neurological illnesses (e.g., stroke, seizure history), autoimmune disorders, and severe psychiatric diseases (e.g., schizophrenia) will be excluded. Participants with any history of brain surgery, tumor, intracranial metal implantation, pacemakers or other implanted devices will be excluded.
- Sleep medications and/or psychostimulants are exclusionary. Subjects in the older cohort will NOT be excluded for taking blood pressure and cholesterol medication. Participants who are pregnant will be excluded. If participants have a history of adverse reaction to electrical nerve stimulation, they will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Younger Cohort
Healthy individuals aged 18 - 55
|
vagal nerve stimulation
|
|
Active Comparator: Older Cohort
Healthy individuals aged 56 - 85
|
vagal nerve stimulation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
System Usability Scale
Time Frame: Day 7 reported
|
This is a standard version of a usability scale.
Subjects will be given 10 statements regarding the usability of the equipment they used, and they will report how much they agree with each statement on a 1 - 5 scale (1 is strongly disagree and 5 is strongly agree).
The score range is 10-50 where 50 demonstrates the highest acceptance of the usability of the device and 10 demonstrates the lowest acceptance of the usability of the device.
|
Day 7 reported
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- IRB201901518 -A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Performance
-
NCT07407426Not yet recruitingStress | Performance | Cognitive Performance | Cognitive Abilities
-
NCT07466654CompletedAnaerobic Performance Neuromuscular Performance Cognitive Performance
-
NCT05904431Not yet recruitingCognitive Performance | Physical Performance
-
NCT07580248CompletedCognitive Performance | Physical Performance
-
NCT06684808CompletedAcademic Acheivement | Cognitive Performance | Physical Performance
-
NCT07400432Enrolling by invitationCognitive Performance | Cognitive Performance During Physical Activity | Sustained Attention
-
NCT07548541CompletedHealthy Volunteers | Cognitive Performance | Anaerobic Performance
-
NCT05032729CompletedSleep | Cognitive Performance | Balance | Physical Performance
-
NCT07562256CompletedAthletic Performance | Cognitive Performance | Healthy Adult Females
-
NCT06606925Recruiting
Clinical Trials on Transcutaneous Vagal Nerve Stimulation (tVNS)
-
NCT04810234RecruitingfMRI | Transcutaneous Vagal Nerve Stimulation (tVNS) | Nucleus of the Solitary Tract (NTS)
-
NCT07131696Not yet recruitingAneurysmal Subarachnoid Hemorrhage | Endovascular Treatment | Vasospasm, Cerebral | Transcutaneous Vagal Nerve Stimulation (tVNS)
-
NCT06292962CompletedDiabetes Mellitus | Diabetic Neuropathies | Neuropathic Pain | Type2diabetes
-
NCT04632134RecruitingPhysical Disability | Orthostatic Intolerance | Postural Tachycardia Syndrome | Autonomic Dysfunction | Syncope, Postural
-
NCT01627301RecruitingPrehypertension | Post-traumatic Stress Disorder
-
NCT03180554CompletedChronic Widespread Pain | Fibromyalgia
-
NCT06985628CompletedDyspnea | Chronic Obstructive Pulmonary Disease Severe
-
NCT07404852RecruitingAcute Ischemic Stroke | Large Vessel Occlusion